press release
July 3, 2012, 10:00 a.m. EDT
Stem Cell Therapy Shown to be Effective in Treating Liver Cirrhosis
New Published Research Finds Improvement in Liver Function in Patient with Primary Biliary Cirrhosis
SHENZHEN, China, July 3, 2012 /PRNewswire via COMTEX/ -- A study conducted by
Beike Biotechnology Company ( http://www.beikebiotech.com ) in conjunction with
physicians and researchers at two Chinese hospitals, documents the effectiveness
of cord blood-derived stem cells in treating primary biliary cirrhosis (PBC).
The study, which was published in the April 2012 issue of the Stem Cell
Discovery, was the first of its kind. Researchers noted that additional clinical
trials would be required before stem cells can become an accepted therapy for
liver cirrhosis.
Prof. Jin-hui Yang, Director of the Department of Hepatology in the 2nd
Affiliated Hospital of Kunming Medical College stated, "Given the severity of
liver cirrhosis and its related conditions, and the limited number of options
available to treat those who suffer from it, this finding represents an
important, potentially significant breakthrough."
PBC is a chronic, progressive liver disease that leads eventually to fibrosis
and cirrhosis of the liver. It affects 1 in 1,000 women over the age of 40.
Approximately one-third of those who suffer from PBC and its related conditions
do not respond well to Ursodeoxycholic acid (UDCA) treatment, which is the only
currently FDA-approved standard medical treatment for the condition. Many of
those patients ultimately require liver transplantation.
Beike Chairman, Dr. Sean Hu, commented, "With a growing body of research that
demonstrates the effectiveness of cord blood-derived stem cell therapies in
treating a broad range of chronic conditions, this latest study is a milestone
in the continuing effort to gain broad acceptance and recognition of
regenerative medicine as a mainstream treatment option. We look forward to
conducting more comprehensive clinical trials to attempt to validate the
positive outcomes we have already observed."
The case study reported in the Stem Cell Discovery involved a 58 year old
woman suffering from PBC who developed an incarcerated hernia and uncontrolled
hydrothorax after undergoing UDCA treatment. One week after completing two stem
cell transplantations with no observed adverse effects, the patient showed
improvement in both liver function and in her general condition. She was
released from the hospital but continued to receive twice-daily UDCA treatments.
Six months after her discharge, doctors observed continued improvements in her
liver function and overall condition.
To review the full text of the published study, please visit:
http://www.scirp.org/journal/PaperInformation.aspx?paperID=18710 . Study authors
included physicians and researchers from the 2nd Affiliated Hospital of Kunming
Medical College, Beike Biotechnology Company, and the Yunnan Provincial 1st
People's Hospital in Kunming, China.
About Beike Biotechnology Company
Shenzhen Beike Biotechnology Co., Ltd. is China's leading biotechnology
company focusing on the production of adult stem cells for use in medical
therapies. Headquartered in Shenzhen (near Hong Kong) with a flagship
regenerative medicine facility at the China Medical City in Jiangsu province,
Beike produces a full line of stem cell products derived from umbilical cord,
cord blood and autologous bone marrow.
For any questions regarding this release, please call:
Contact Person:T. GutmannPhone Number: +86-532-6677-6659
SOURCE Beike Biotechnology Co. Ltd.
Copyright (C) 2012 PR Newswire. All rights reserved
No comments:
Post a Comment